Clinical trials: MEASLES DISEASE
Measles, Rubella
Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
This is a study to evaluate the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals combined measles-mumps-rubella varicella candidate vaccine given to healthy children in their second year of life.
- Conditions
- Measles, Rubella, Mumps, Varicella
- Trial name
- NCT00127010
- Testing
- Measles, Mumps, Rubella and Chickenpox (live vaccine)
- Where
- 48 sites in Belgium, Germany and 1 more
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Immunotoxicity, Vaccine
Clinical Trial of Measles, Mumps and Rubella Combined Vaccine, Live
To evaluate the immunogenicity, lot-to-lot consistency and safety of three consecutive batches of Measles, Mumps and Rubella Combined Vaccine, Live.
- Trial name
- NCT05161845
- Testing
- Measles, Mumps and Rubella Combined Vaccine, Live
- Where
- China
- Volunteers
- 1,068 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute Of Biological Products
Measles, Mumps
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life
The purpose of this study is to evaluate end of shelf-life potency in terms of the immunogenicity and safety of GSK Biologicals' trivalent MMR vaccine, by comparing it to Merck \& Co., Inc.'s MMR vaccine, which is approved for…
- Conditions
- Measles, Mumps, Rubella, Measles-Mumps-Rubella Vaccine
- Trial name
- NCT01681992
- Testing
- Priorix, M-M-R II, Varivax
- Where
- 81 sites in United States, Czechia and 5 more
- Volunteers
- 4,538 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Meningococcal Meningitis, Measles
Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers
This clinical trial will evaluate the safety of two injections of Menactra® Vaccine in subjects at 9 months and at 12 months of age when the second dose is given concomitantly with other pediatric vaccines routinely administered…
- Conditions
- Meningococcal Meningitis, Measles, Mumps, Rubella
- Trial name
- NCT00483574
- Testing
- Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate, Measles-mumps-rubella-varicella vaccine, Routine paediatric vaccine - Pneumococcal conjugate (PCV)
- Where
- 79 sites in United States, Chile
- Volunteers
- 1,378 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Mumps, Rubella
Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™
Since measles-mumps-rubella (MMR) and varicella vaccinations are established as routine childhood practice and often co-administered during the second year of life, a combined measles-mumps-rubella-varicella (MeMuRu-OKA) vaccine…
- Conditions
- Mumps, Rubella, Measles, Varicella
- Trial name
- NCT00352898
- Testing
- MeMuRu-OKA (study vac), MMR, Varicella vacc (control)
- Where
- 6 sites in Canada, Italy
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria, Malaria Vaccines
Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.
The purpose of this study is to assess the immunogenicity, safety, and reactogenicity of the SB257049 candidate malaria vaccine when co-administered with Vitamin A, measles, rubella and yellow fever vaccines to children aged 6…
- Trial name
- NCT02699099
- Testing
- Vitamin A, Candidate Plasmodium falciparum malaria vaccine, MR-Vac
- Where
- 2 sites in Ghana
- Volunteers
- 699 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Measles, Rubella
Measles and Rubella Vaccine Microneedle Patch Phase 1-2 Age De-escalation Trial
This is a phase 1/2, single-centre, double-blind, double-dummy, randomized, active-controlled, age de-escalation trial. Age de-escalation will be based on a review of the safety data from the preceding cohort (adults for toddlers…
- Conditions
- Measles, Rubella, Vaccination, Healthy
- Trial name
- NCT04394689
- Testing
- Measles Rubella Vaccine (MRV-SC), MRV-MNP, PLA-MNP
- Where
- The Gambia
- Volunteers
- 281 people, healthy volunteers welcome
- Sponsor
- Micron Biomedical, Inc
Malaria
Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen
This study is being done to assess the possibility of the potential integration of malaria vaccine into the EPI regimen. It will evaluate whether the malaria vaccine is safe and immunogenic in infants aged 6 to 10 weeks at first…
- Trial name
- NCT00436007
- Testing
- GSK 257049, Tritanrix™ HepB/Hib, Rouvax™
- Where
- 3 sites in Gabon, Ghana and 1 more
- Volunteers
- 511 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Measles, Mumps
Immunogenicity/Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA): Using Two Different Administration Routes
This study will compare the immunogenicity and safety of the MeMuRu-OKA vaccine administered subcutaneously or using an alternative administration route.
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00351923
- Testing
- MeMuRu-OKA (study vaccine)
- Where
- 20 sites in Germany
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Vaccine
Evaluation of Immunogenicity and Safety of Combined Immunization of sIPV, DTaP and MMR
Eligible,healthy infants who have finished the 3-dose-schedule of sIPV+DTaP combined vaccination clinical trial (NCT04054882) will be recruited and divided into 4 groups, and will receive vaccination at the age of 18-month-old as…
- Trial name
- NCT04638985
- Testing
- sIPV+DTaP+MMR, sIPV, DTaP
- Where
- 3 sites in China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Measles, Varicella
Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136
This Phase 3b study is being conducted for the purpose of registration of the GSK208136 vaccine in Korea.
- Conditions
- Measles, Varicella, Mumps, Rubella
- Trial name
- NCT00751348
- Testing
- PriorixTM, VarilrixTM, Priorix-Tetra®
- Where
- 13 sites in South Korea
- Volunteers
- 475 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Japanese Encephalitis, Measles
Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers
This study is designed to compare the immunogenicity of Japanese encephalitis chimeric virus vaccine (JE-CV) and measles-mumps-rubella (MMR)vaccine when given together or when given at separate visits 6 weeks apart in toddlers…
- Conditions
- Japanese Encephalitis, Measles, Mumps, Rubella
- Trial name
- NCT01188343
- Testing
- Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus
- Where
- 3 sites in Taiwan
- Volunteers
- 542 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Varicella, Rubella
Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™
As measles-mumps-rubella (MMR) vaccination is established as routine childhood practice in most industrialised countries and varicella vaccination is now being introduced in many countries during the second year of life, a…
- Conditions
- Varicella, Rubella, Measles, Mumps
- Trial name
- NCT00353288
- Testing
- MeMuRu-OKA (study vacc), MMR, Varicella vacc (control)
- Where
- 39 sites in France, Germany and 1 more
- Volunteers
- 446 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Trial to Assess Safety, Efficacy, Tolerability and Immunogenicity of Influenza Virus Vaccine, Liquid Formulation (CAIV-T), Administered Concomitantly With a Combination Live, Attenuated, Mumps, Measles, and Rubella Vaccine in Healthy Children Aged 11 - 24 Months
The primary objective of the study was to determine if intranasally administered influenza virus vaccine, CAIV-T), when administered concomitantly with a subcutaneously administered combination live, attenuated mumps, measles…
- Trial name
- NCT00192166
- Testing
- CAIV-T
- Where
- Singapore
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Measles, Mumps
Immunogenicity and Safety of Concomitant Administration of MMR™ rHA and VARIVAX® by Intramuscular Versus Subcutaneous Route (V205C-011)
Primary objective: To compare if, when given concomitantly with VARIVAX® by the same route at 12-18 months of age using separate injection sites, a single dose of M-M-RTMII administered by IM route is as immunogenic as a single…
- Conditions
- Measles, Mumps, Varicella
- Trial name
- NCT00432523
- Testing
- M-M-R™II manufactured with recombinant Human Albumin (rHA) and VARIVAX®
- Where
- 2 sites in France, Germany
- Volunteers
- 752 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Measles, Mumps
A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014)
The study was conducted to determine if ProQuad may be used in place of the second dose of M-M-R II routinely given to children 4 to 6 years old who were previously immunized with M-M-R II and Varivax.
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00985166
- Testing
- ProQuad (Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live), Comparator: M-M-R II, Comparator: Varivax
- Volunteers
- 801 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
COVID-19
Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine
This is a randomized, placebo-controlled, two center, Phase I trial in healthy adult volunteer participants consisting of two phases, an unblinded dose escalation and a double blind treatment phase to investigate the safety…
- Trial name
- COVID-19-101 (NCT04497298)
- Testing
- Two COVID-19 vaccine candidate (TMV-083/V-591) administrations - Low dose, Two COVID-19 vaccine candidate (TMV-083/V-591) administrations - High dose, One COVID-19 vaccine candidate (TMV-083/V-591) administration - High dose
- Where
- 2 sites in Belgium, France
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Acute Bacterial Infections, Acute Viral Infections
300 Antibody Diagnostic Test Kit
For the development of a Point of Care IVD test kit for acute phase disease detection against a variety of bacterial and viral infections.
- Trial name
- Antibody 300 (NCT01646411)
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- The Plasma Source
Prophylaxis for the Measles Infection
A Clinical Trial to Assess the Safety of a Measles Vaccine (Dry Powder) Administered by Two Different Devices
This is a phase I, open-label, randomized study in healthy adults. Eligible subjects will be given single dose of either Dry Powdered Measles Vaccine (PMV) by Puffhaler® device, Dry PMV by SoloventTM device or licensed measles…
- Trial name
- PMV-001 (NCT01557699)
- Testing
- PMV via Puffhaler® device, PMV via SoloventTM device, Licensed Subcutaneous Measles Vaccine
- Where
- India
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Rubella, Varicella
Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children
The purpose of this study is to assess the immunogenicity and safety of GSK Biologicals' investigational measles, mumps, rubella and varicella (MMRV) vaccine (GSK208136, PriorixTetra™) when co-administered along with conjugated…
- Conditions
- Rubella, Varicella, Measles, Mumps
- Trial name
- NCT01506193
- Testing
- PriorixTetra™, Meningitec
- Where
- 13 sites in Italy
- Volunteers
- 716 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline